Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)

被引：6

作者：

Gupta, S. ^{[1
]}

Climent Duran, M. A. ^{[2
]}

Sridhar, S. ^{[3
]}

Powles, T. B. ^{[4
]}

Bellmunt, J. ^{[5
]}

Tyroller, K. ^{[6
]}

Guenther, S. ^{[7
]}

di Pietro, A. ^{[8
]}

Grivas, P. ^{[9
]}

机构：

[1] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA

[2] Inst Valenciano Oncol, Valencia, Spain

[3] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med Ctr, St Bartholomews Hosp, London, England

[5] Dana Farber Canc Inst, Harvard Med Sch, Dept Med Oncol, Boston, MA USA

[6] EMD Serono Res & Dev Inst Inc, Billerica, MA USA

[7] Merck Healthcare KGaA, Darmstadt, Germany

[8] Pfizer Srl, Milan, Italy

[9] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2371P

引用

页码：S1207 / S1207

页数：1

共 50 条

[1] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes [J].

Loriot, Yohann ;

Gupta, Shilpa ;

Powles, Thomas ;

Grivas, Petros ;

Petrylak, Daniel P. ;

Tyroller, Karin ;

Jacob, Natalia ;

Hoffman, Jason ;

Bellmunt, Joaquim .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[2] Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial. [J].

Bellmunt, Joaquim ;

Aragon-Ching, Jeanny B. ;

Climent, Miguel Angel ;

Sridhar, Srikala S. ;

Powles, Thomas ;

Cislo, Paul ;

Michelon, Elisabete ;

Di Pietro, Alessandra ;

Grivas, Petros .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[3] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI) [J].

Aragon-Ching, Jeanny B. ;

Petrylak, Daniel P. ;

Sridhar, Srikala S. ;

Gupta, Shilpa ;

Grivas, Petros ;

Powles, Thomas ;

Gurney, Howard ;

Jacob, Natalia ;

Tyroller, Karin ;

Guenther, Silke ;

Bellmunt, Joaquim .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) :600-600

[4] Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients [J].

Gupta, S. ;

Duran, M. A. Climent ;

Sridhar, S. S. ;

Powles, T. ;

Bellmunt, J. ;

Park, S. H. ;

Gurney, H. ;

Tsuchiya, N. ;

Petrylak, D. P. ;

Tomita, Y. ;

di Pietro, A. ;

Manitz, J. ;

Tyroller, K. ;

Hoffman, J. ;

Jacob, N. ;

Grivas, P. .

ESMO OPEN, 2025, 10 (04)

[5] Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100 [J].

Grivas, P. ;

Park, S. H. ;

Voog, E. ;

Su, W-P. ;

Demey, W. ;

Fong, P. C. ;

Garcia, J. A. ;

Jacob, N. ;

Gerhold-Ay, A. ;

Tyroller, K. ;

Hoffman, J. ;

Bellmunt, J. ;

Powles, T. B. .

ANNALS OF ONCOLOGY, 2024, 35 :S1144-S1144

[6] Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC) [J].

Powles, T. B. ;

Sridhar, S. ;

Bellmunt, J. ;

Sternberg, C. ;

Grivas, P. ;

Hunter, E. ;

Dezfouli, M. ;

Salter, M. ;

Powell, R. ;

Dring, A. ;

Green, J. ;

Akoulitchev, A. ;

Amezquita, R. ;

Ching, K. ;

Pu, J. ;

Deng, S. ;

di Pietro, A. ;

Davis, C. B. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S1442-S1442

[7] Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden [J].

Bellmunt, Joaquim ;

Powles, Thomas ;

Park, Se Hoon ;

Voog, Eric ;

Valderrama, Begona Perez ;

Gurney, Howard ;

Ullen, Anders ;

Loriot, Yohann ;

Sridhar, Srikala S. ;

Tsuchiya, Norihiko ;

Sternberg, Cora N. ;

Aragon-Ching, Jeanny B. ;

Petrylak, Daniel P. ;

Duran, Miguel A. Climent ;

Tyroller, Karin ;

Hoffman, Jason ;

Jacob, Natalia ;

Grivas, Petros ;

Gupta, Shilpa .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[8] AVELUMAB FIRST-LINE (1L) MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA (UC): LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY RESPONSE TO 1L CHEMOTHERAPY [J].

Valderrama, Begona ;

Powles, Thomas ;

Sridhar, Srikala ;

Caserta, Claudia ;

Loriot, Yohann ;

Gupta, Shilpa ;

Bellmunt, Joaquim ;

Sternberg, Cora ;

Wang, Jing ;

Costa, Nuno ;

Laliberte, Robert ;

di Pietro, Alessandra ;

Park, Se Hoon ;

Grivas, Petros .

JOURNAL OF UROLOGY, 2023, 209 :E244-E244

[9] Avelumab first-line (1 L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1 L chemotherapy [J].

Valderrama, Begona P. ;

Powles, Thomas ;

Sridhar, Srikala S. ;

Caserta, Claudia ;

Loriot, Yohann ;

Gupta, Shilpa ;

Bellmunt, Joaquim ;

Sternberg, Cora N. ;

Pook, David W. ;

Wang, Jing ;

Costa, Nuno ;

Laliberte, Robert J. ;

di Pietro, Alessandra ;

Park, Se Hoon ;

Grivas, Petros .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 :139-139

[10] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Longterm outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy. [J].

Perez-Valderrama, Begona ;

Powles, Thomas ;

Sridhar, Srikala S. ;

Caserta, Claudia ;

Loriot, Yohann ;

Gupta, Shilpa ;

Bellmunt, Joaquim ;

Sternberg, Cora N. ;

Wang, Jing ;

Costa, Nuno ;

Laliberte, Robert J. ;

Di Pietro, Alessandra ;

Park, Se Hoon ;

Grivas, Petros .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →